[Skip to Navigation]
Sign In

January 2021 - April 2015

Decade

Year

Issue

December 2020, Vol 6, No. 12, Pages 1838-1985

Original Investigation

Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(12):1881-1889. doi:10.1001/jamaoncol.2020.5403

This decision analytical model uses a web-based application and data from the Surveillance, Epidemiology, and End Results program to quantitatively integrate mortality estimates and to examine the impact of cancer treatment delay among adults with cancer during the coronavirus disease 2019 pandemic.

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

Abstract Full Text
has active quiz has audio
JAMA Oncol. 2020;6(12):1890-1899. doi:10.1001/jamaoncol.2020.4600

This meta-analysis examines the use of measurable residual disease as an end point in studies to assess survival outcomes in patients with acute myeloid leukemia.

Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases

Abstract Full Text
JAMA Oncol. 2020;6(12):1901-1909. doi:10.1001/jamaoncol.2020.4630

This cohort study looks at outcomes and prognostic factors associated with overall survival and local control after hypofractionated stereotactic radiotherapy to the resection cavity of patients with brain metastases.

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate

Abstract Full Text
JAMA Oncol. 2020;6(12):1912-1920. doi:10.1001/jamaoncol.2020.4922

This cohort study develops and validates a pretreatment clinical prognostic stage group system for patients with nonmetastatic prostate cancer.

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(12):1923-1930. doi:10.1001/jamaoncol.2020.4574

This randomized clinical trial examines the efficacy of weekly paclitaxel with or without bevacizumab as treatment for relapsed sex cord-stromal tumors and whether the addition of bevacizumab to weekly paclitaxel improves 6-month progression-free rates.

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(12):1931-1938. doi:10.1001/jamaoncol.2020.4643

This clinical trial assesses the clinical use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing results, for Japanese patients with cancer of unknown primary site.

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(12):1939-1946. doi:10.1001/jamaoncol.2020.3161

This randomized clinical trial compares overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care.

Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2020;6(12):e204759. doi:10.1001/jamaoncol.2020.4759

This stepped-wedge cluster randomized clinical trial assesses the effect of a clinician-directed intervention combining machine learning mortality predictions with behavioral nudges vs usual care on motivating serious illness conversations between clinicians and patients with cancer.

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis

Abstract Full Text
online only
JAMA Oncol. 2020;6(12):e204930. doi:10.1001/jamaoncol.2020.4930

This systematic review with meta-analysis compares the effectiveness of different vascular endothelial growth factor inhibitors, checkpoint inhibitors, or their combinations in patients with advanced hepatocellular carcinoma in the first-line or refractory settings.

Brief Report

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

Abstract Full Text
open access
JAMA Oncol. 2020;6(12):1947-1951. doi:10.1001/jamaoncol.2020.4508

This case series evaluates pembrolizumab concentrations and programmed cell death 1 blockade on T cells in cerebrospinal fluid after intravenous administration.

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1952-1956. doi:10.1001/jamaoncol.2020.5012

This multicenter cohort study characterizes the spectrum of multisystem immune-related adverse events, their association with survival, and risk factors for development, in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.

Research Letter

Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia

Abstract Full Text
JAMA Oncol. 2020;6(12):1969-1970. doi:10.1001/jamaoncol.2020.4660

This cohort study identifies trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia and the association those treatment choices have with health care costs.

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1971-1972. doi:10.1001/jamaoncol.2020.4749

This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.

Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma

Abstract Full Text
JAMA Oncol. 2020;6(12):1972-1974. doi:10.1001/jamaoncol.2020.4937

This cohort study evaluates the national practice patterns of MGMT gene testing and identified potential factors associated with access to testing.

Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort

Abstract Full Text
JAMA Oncol. 2020;6(12):1974-1976. doi:10.1001/jamaoncol.2020.5018

This cohort study examines the association between aspirin use and cholangiocarcinoma in an Asian cohort.

Review

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review

Abstract Full Text
JAMA Oncol. 2020;6(12):1957-1966. doi:10.1001/jamaoncol.2020.4401

This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights results from clinical trials exploring these approaches.

JAMA Oncology Clinical Challenge

Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(12):1967-1968. doi:10.1001/jamaoncol.2020.2693

A 48-year-old man with a history of rectal adenocarcinoma and multiple lung metastases presents with a 1-cm posterior subglottic lesion of unclear origin found on restaging scans. What is your diagnosis?

Viewpoint

Efficacy, Improved Quality of Life, and Cost-effectiveness of Partial Breast Irradiation: A Triple-Threat Approach

Abstract Full Text
JAMA Oncol. 2020;6(12):1859-1860. doi:10.1001/jamaoncol.2020.0795

This Viewpoint provides an evaluation of partial breast irradiation as an alternative to standard and hypofractionated whole-breast irradiation in terms of its ability to reduce duration of treatment and provide equivalent outcomes, comparable or reduced adverse effects, and cost-effectiveness

Hospital Deaths a Poor Quality Metric for Patients With Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1861-1862. doi:10.1001/jamaoncol.2020.1043

This Viewpoint explores whether hospital death rates should still be considered an appropriate quality metric when it comes to the care of patients with cancer.

Trends in Deescalation of Localized Breast Cancer Treatment and Caution for the Most Vulnerable Patients—A Look Back on the Decade That Was

Abstract Full Text
JAMA Oncol. 2020;6(12):1863-1864. doi:10.1001/jamaoncol.2020.1821

This Viewpoint discusses calls to deescalate therapy and omit radiation in the setting of pathologic complete response for patients with breast cancer.

The Public Health Standard in Action—Analysis of the US Food and Drug Administration’s IQOS Review

Abstract Full Text
JAMA Oncol. 2020;6(12):1864-1865. doi:10.1001/jamaoncol.2020.3316

This Viewpoint describes 3 issues to be considered before upcoming US Food and Drug Administration reviews of electronic cigarette products.

Editorial

To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(12):1868-1869. doi:10.1001/jamaoncol.2020.4886
Invited Commentary

Minimal Residual Disease in Acute Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2020;6(12):1899-1900. doi:10.1001/jamaoncol.2020.4599

Stereotactic Radiotherapy and Resection of Brain Metastases: The Role of Hypofractionation

Abstract Full Text
JAMA Oncol. 2020;6(12):1910-1911. doi:10.1001/jamaoncol.2020.4400

Improving Pretreatment Risk Prognostication in Localized Prostate Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1921-1922. doi:10.1001/jamaoncol.2020.4916
Cancer Care Chronicles

On Trauma, Resilience, and Survival—Lessons From 15 Years of Pediatric Cancer and Remission

Abstract Full Text
JAMA Oncol. 2020;6(12):1866-1867. doi:10.1001/jamaoncol.2020.3392

This essay details the the emotional toll of pediatric cancer from the author’s peronal experiences and uses these details to correct misconceptions many have about patients who die from or survive the disease.

Comment & Response

Survival and Outcomes After Noncompletion of Treatment for Anal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1976-1977. doi:10.1001/jamaoncol.2020.3949

Survival and Outcomes After Noncompletion of Treatment for Anal Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1977. doi:10.1001/jamaoncol.2020.3952

Survival and Outcomes After Noncompletion of Treatment for Anal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(12):1977-1978. doi:10.1001/jamaoncol.2020.3963

Appropriate Analysis of Duration of Response Data in Cancer Trials

Abstract Full Text
JAMA Oncol. 2020;6(12):1978. doi:10.1001/jamaoncol.2020.4657

Appropriate Analysis of Duration of Response Data in Cancer Trials—Reply

Abstract Full Text
JAMA Oncol. 2020;6(12):1978-1979. doi:10.1001/jamaoncol.2020.4664

Important Concerns Over SARS-CoV-2 Infection in Children With Cancer

Abstract Full Text
free access
JAMA Oncol. 2020;6(12):1979-1980. doi:10.1001/jamaoncol.2020.4756

Important Concerns Over SARS-CoV-2 Infection in Children With Cancer—Reply

Abstract Full Text
free access
JAMA Oncol. 2020;6(12):1980. doi:10.1001/jamaoncol.2020.4767

Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer

Abstract Full Text
JAMA Oncol. 2020;6(12):1981. doi:10.1001/jamaoncol.2020.4815

Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(12):1981-1982. doi:10.1001/jamaoncol.2020.4821

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers

Abstract Full Text
JAMA Oncol. 2020;6(12):1982. doi:10.1001/jamaoncol.2020.4818

Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply

Abstract Full Text
JAMA Oncol. 2020;6(12):1983. doi:10.1001/jamaoncol.2020.4824

Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma

Abstract Full Text
JAMA Oncol. 2020;6(12):1983-1984. doi:10.1001/jamaoncol.2020.5158

Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma—Reply

Abstract Full Text
JAMA Oncol. 2020;6(12):1984. doi:10.1001/jamaoncol.2020.5167

Errors in Hazard Ratios, Labels in Figures, and Text

Abstract Full Text
JAMA Oncol. 2020;6(12):1984-1985. doi:10.1001/jamaoncol.2020.7074
Correction

Errors in Hazard Ratios, Labels in Figures, and Text

Abstract Full Text
free access
JAMA Oncol. 2020;6(12):1985. doi:10.1001/jamaoncol.2020.7078

Error in Funding/Support

Abstract Full Text
free access
JAMA Oncol. 2020;6(12):1985. doi:10.1001/jamaoncol.2020.5699
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(12):1838. doi:10.1001/jamaoncol.2019.4263
×